Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, announced today the launch of its new SmartPak II™ Condition Monitoring System. It is configured to provide end-to-end visibility on the real-time condition and location of critical biological commodities. The SmartPak IITM measures a variety of environmental variables and works in conjunction with the Company's Cryoportal™ logistics management platform to provide comprehensive and seamless monitoring of commodity conditions and Cryoport Express™ shipper performance. The cloud based Cryoportal™ retains all of the critical data analytics generated by the SmartPak IITM, including "chain-of-condition" and "chain-of-custody". Its seamless integration with the Cryoportal™ provides, for the first time, real-time intervention capabilities. Automated email alerts are sent to stakeholders for any incident of excursion or deviation.
The ground breaking research in cancer immunotherapies and regenerative medicine now dictate strict temperature and timeline compliance for all biologic materials transported around the globe. The SmartPak II™ is an advanced integrated monitoring and communications systems that tracks the key aspects of each shipment that could affect the quality and/or timing of delivery of the commodity to its intended destination. This includes industry leading real-time tracking using the Global Positioning System (GPS), cellular technology and Wi-Fi triangulation, which assures communication even in signal impaired environments. Some variables measured by the SmartPak II™ include internal and external temperatures, pressure, humidity, shock and orientation of the shipper. Additionally, the SmartPak IITM system provides Cryoport with the ability to correlate transit related events to the impact on sample integrity, providing valuable insight on crucial logistics planning and equipment performance.
As an example of its value, during its Beta phase, the SmartPak II™ Condition Monitoring System benefited a client by having a shipment saved during transit. In this instance, the SmartPak II TM notified our client care team of an orientation issue during a critical shipment from the United States to the Netherlands. Due to the alert sent by the SmartPak II™, Cryoport logistics management was able to intervene and ensure that the materials arrived safely for the scheduled patient procedure. The Smart Pak II TM will be fully available to Cryoport's customers effective August 31st, 2016.
Jerrell Shelton, CEO of Cryoport, said, "Our SmartPak II™ Condition Monitoring System is one of Cryoport's latest technology innovations. It is a 'system' which includes much more than traditional data logging; it is a leap forward from anything that is in the market today. We expect it to have a significant impact on cold-chain logistics for the life sciences industry as it is so comprehensive. The SmartPak II™ provides clients with a consistent, real time data stream of crucial information and unparalleled visibility on the condition and status of their commodities through out the logistics process. Made possible through our advanced, integrated technologies, Cryoport can detect and provide information to circumvent unforeseen circumstances that could and do occur during the logistics process. By offering real time visibility of Cryoport Express™ shippers and the ability to "communicate" with the shippers, Cryoport is redefining effectiveness for quality control and regulatory compliance supporting new immunotherapies and regenerative medicine, in general.
"Our leading cold-chain logistics solutions for the life sciences have become essential tools for the logistics of temperature sensitive commodities. To our knowledge, we are "un-matched" in the science, technology and engineering behind our solutions and services. We are committed to continuous improvement in our capabilities and to supplying solutions that the global life sciences market is demanding," concluded Mr. Shelton.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.
